Pr. Christophe Hirtz has been working on Clinical Proteomics since 2000 and was one of the first to publish the complexity of the human salivary proteome (Hirtz et al., 2005) using mass spectrometry. Since then, he is specialized in clinical assays and R&D activities in the field of clinical proteomics and neurodegenerative diseases since 2010. He was technician between 1998 and 2007, then Engineer (2007-2009), associate professor (2009-2017) and then professor (2017-). He is recognized as an expert in high resolution proteomics for identification and quantification of biomarkers (Bottom-up/Top-down), in targeted mass spectrometry for multiplexed and absolute quantification of biomarkers, and in multiplexed and ultra-sensitive immunodetection. He is involved in the discovery, validation, and use of clinical biomarkers in many pathologies. He is coordinator of several academic projects including in 2019 a PRRI FEDER “SMART” funding (1000 K€), a France Alzheimer “Plasma Boost” funding (100K€) and participated in obtaining 4500 K€ of funding since 2011. He is currently responsible of the Clinical Proteomics Platform of Montpellier hospital and Montpellier University, part of the Shimadzu European Innovation Center and considered as a key opinion in the field of the clinical mass spectrometry. Christophe Hirtz is member of the « Société Française d’Electrophorèse et Analyse Protéomique (SFEAP) », member of the Joint Program – Neurodegenerative Disease (JPND), member of the European consortium EMPIR (15HLT04) NeuroMet and member of the European workgroup IFCC « development of a clinical MS-based reference system for standardization of multiple serum apolipoproteins ». He published more than 130 international scientific articles (H factor: 33, >4600 citations, 3 international patent) and obtained reward for Scientific Excellence (Montpellier University 2014-2018 and 2019-2023)